Smith & Nephew PLC
Fermé
1,007 -1.32
Résumé
Variation du prix de l'action
24h
Min
1007
Max
1014.5
Revenu | -42M 301M |
|---|---|
Ventes | -234M 3.1B |
P/E Moyenne du Secteur | 19.824 32.138 |
Rendement du dividende | 3.73 |
Marge bénéficiaire | 9.784 |
Employés | 17,000 |
EBITDA | -113M 773M |
Rendement du dividende Moyenne du Secteur | 3.73% 3.59% |
|---|---|
Date du Prochain Dividende | 6 nov. 2026 |
Date du Prochain Détachement de Dividende | 1 oct. 2026 |
Capitalisation Boursière | -390M 9B |
|---|---|
Ouverture précédente | 1008.32 |
Clôture précédente | 1007 |
Smith & Nephew PLC Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Smith & Nephew PLC prévision
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
